Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

Diabetes Care ◽

10.2337/dc12-0706 ◽

2012 ◽

Vol 36 (2) ◽

pp. 237-244 ◽

Author(s):

J. B. McGill ◽

L. Sloan ◽

J. Newman ◽

S. Patel ◽

C. Sauce ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Faculty Opinions recommendation of Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717961956.793465689 ◽

2012 ◽

Author(s):

Pierre Ronco ◽

Jean-Jacques Boffa

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12403 ◽

2015 ◽

Vol 17 (2) ◽

pp. 152-160 ◽

Author(s):

A. Kashiwagi ◽

H. Takahashi ◽

H. Ishikawa ◽

S. Yoshida ◽

K. Kazuta ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Renal Impairment ◽

Safety Evaluation ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension

Diabetes Obesity and Metabolism ◽

10.1111/dom.12235 ◽

2013 ◽

Vol 16 (5) ◽

pp. 418-425 ◽

Author(s):

T. Kadowaki ◽

K. Kondo

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study

Indian Journal of Endocrinology and Metabolism ◽

10.4103/ijem.ijem_517_16 ◽

2017 ◽

Vol 21 (2) ◽

pp. 286 ◽

Author(s):

Viraj Suvarna ◽

Sunil Gupta ◽

Shehla Shaikh ◽

Pooja Joshi ◽

Shraddha Bhure

Keyword(s):

Type 2 Diabetes ◽

Randomized Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Term Efficacy ◽

Drug Naïve ◽

Extension Trial

Download Full-text

A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (BAYg 5421) in the treatment of obese patients with NIDDM treated by diet alone

New Aspects in Diabetes ◽

10.1515/9783110859447-020 ◽

1992 ◽

pp. 233-233

Author(s):

R. F. Coniff

Keyword(s):

Controlled Study ◽

Obese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2011.01391.x ◽

2011 ◽

Vol 13 (7) ◽

pp. 653-661 ◽

Author(s):

R. Gomis ◽

R.-M. Espadero ◽

R. Jones ◽

H. J. Woerle ◽

K. A. Dugi

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Initial Combination Therapy ◽

Initial Combination

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion ◽

10.1185/03007990903156111 ◽

2009 ◽

Vol 25 (10) ◽

pp. 2361-2371 ◽

Author(s):

Richard E. Pratley ◽

Jane E.-B. Reusch ◽

Penny R. Fleck ◽

Craig A. Wilson ◽

Qais Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

Diabetology International ◽

10.1007/s13340-014-0182-y ◽

2014 ◽

Vol 6 (2) ◽

pp. 104-116 ◽

Author(s):

Atsunori Kashiwagi ◽

Takanori Shiga ◽

Noriko Akiyama ◽

Kenichi Kazuta ◽

Atsushi Utsuno ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

Journal of Diabetes Investigation ◽

10.1111/j.2040-1124.2012.00226.x ◽

2012 ◽

Vol 3 (6) ◽

pp. 517-525 ◽

Author(s):

Yutaka Seino ◽

Shinzo Hiroi ◽

Masashi Hirayama ◽

Kohei Kaku

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Extension Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis

Arthritis & Rheumatology ◽

10.1002/art.42010 ◽

2021 ◽

Author(s):

Iain B. McInnes ◽

Proton Rahman ◽

Alice B. Gottlieb ◽

Elizabeth C. Hsia ◽

Alexa P. Kollmeier ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy ◽

Download Full-text